Relapse-free survival. RFS is shown after initial therapy for the total cohort (n = 105; 5 events; median survival, 39.8 months) and the 2 subgroups of patients continuously MRD negative (MRD-neg.; n = 77; 22 events; median survival not reached) or converting to MRD positivity (MRD-pos.; n = 28; 17 events; median, 16.7 months).